A detailed history of Cornerstone Planning Group LLC transactions in Argenx Se stock. As of the latest transaction made, Cornerstone Planning Group LLC holds 22 shares of ARGX stock, worth $13,731. This represents 0.0% of its overall portfolio holdings.

Number of Shares
22
Previous 30 26.67%
Holding current value
$13,731
Previous $14.5 Million 16.32%
% of portfolio
0.0%
Previous 0.0%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 05, 2024

SELL
$434.22 - $551.9 $3,473 - $4,415
-8 Reduced 26.67%
22 $12.2 Million
Q2 2024

Aug 13, 2024

SELL
$356.01 - $451.55 $3,560 - $4,515
-10 Reduced 25.0%
30 $14.5 Million
Q1 2024

May 07, 2024

BUY
$356.95 - $413.29 $1,784 - $2,066
5 Added 14.29%
40 $15.5 Million
Q4 2023

Feb 12, 2024

BUY
$338.91 - $506.01 $338 - $506
1 Added 2.94%
35 $13.3 Million
Q3 2023

Nov 08, 2023

BUY
$369.35 - $548.43 $738 - $1,096
2 Added 6.25%
34 $16.7 Million
Q2 2023

Aug 15, 2023

BUY
$360.14 - $422.58 $11,524 - $13,522
32 New
32 $12.5 Million

Others Institutions Holding ARGX

About ARGENX SE


  • Ticker ARGX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 55,323,800
  • Market Cap $34.5B
  • Description
  • argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, ...
More about ARGX
Track This Portfolio

Track Cornerstone Planning Group LLC Portfolio

Follow Cornerstone Planning Group LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cornerstone Planning Group LLC, based on Form 13F filings with the SEC.

News

Stay updated on Cornerstone Planning Group LLC with notifications on news.